News

Cardio3 starts Phase III
Enlarge image

Clinical trialsBelgiumEU

Cardio3 starts Phase III

23.11.2012 - Belgian Cardio3 BioSciences has received authorisation to begin a European Phase III trial for its autologous stem cell therapy for heart failure.

The Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) Phase III trial will recruit at least 240 patients with chronic advanced symptomatic heart failure, announced the Wallonia-based company on 22 November. The prospective, double-blinded study will compare a treatment with Cardio3’s lead product C3BS-CQR-1 to a sham treatment. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure. 

“We believe C3BS-CQR-1 has the potential to become an alternative to heart transplantat, which is the only curative treatment for heart failure available today“, stated Christian Homsy, CEO of Cardio3 BioSciences adding that – to his knowledge –  this would be the first Phase III trial ever for a regenerative therapy with this indication. "We look forward to confirming the promising results we have already seen in our Phase II study,” concluded Homsy. Cardio3 tested its treatment in Phase II between 2009 and 2010 in multiple clinical sites in Belgium, Serbia and Switzerland.

The therapy involves taking stem cells from a patient’s own bone marrow and re-programming those cells so that they go on to become heart cells. The cardiopoietic cells, are then injected back into the patient’s heart through a minimally invasive procedure using a catheter with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/cardio3-starts-phase-iii.html

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.48 EUR3.77%
  • 4SC1.12 EUR2.75%
  • VITA 344.00 EUR2.04%

FLOP

  • ADDEX2.99 CHF-7.14%
  • BIOFRONTERA2.18 EUR-5.22%
  • SARTORIUS94.26 EUR-3.32%

TOP

  • SANTHERA92.00 CHF43.5%
  • CO.DON3.02 EUR26.9%
  • PAION2.98 EUR19.7%

FLOP

  • EVOTEC3.00 EUR-20.0%
  • ADDEX2.99 CHF-18.5%
  • 4SC1.12 EUR-15.8%

TOP

  • SANTHERA92.00 CHF2211.6%
  • CO.DON3.02 EUR247.1%
  • PAION2.98 EUR189.3%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.23 EUR-41.4%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 16.09.2014